Meral Gunaldi1, Berna Bozkurt Duman2, Cigdem Usul Afsar3, Semra Paydas3, Melek Erkisi3, I Oguz Kara3, Berksoy Sahin3. 1. Department of Medical Oncology, Bakirkoy Research and Training Hospital, Istanbul, Turkey meralgunaldi@gmail.com. 2. Department of Medical Oncology, Adana Research and Training Hospital, Istanbul, Turkey. 3. Department of Medical Oncology, Cukurova University Medical School, Istanbul, Turkey.
Abstract
BACKGROUND: Trastuzumab is a recombinant humanized monoclonal antibody used to treat human epidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic. MATERIALS AND METHODS: The study was made up of 111 women with human epidermal growth factor receptor 2-overexpressing breast cancer who received trastuzumab in the Medical Oncology Department, between 2010 and 2013. RESULTS: A > 10% reduction of the baseline fraction of the left ventricular ejection fraction was observed in 18 (16.21%) women. Two individuals (1.8%) suffered from symptomatic heart failure, seven women showed cardiac symptoms and nine women showed asymptomatic decline of left ventricular ejection fraction. Risk factors for cardiotoxicity in the group included: postmenopausal status (p = 0.01), hypertension (p = 0.002), obesity (p = 0.0001), previously diagnosed coronary artery disease (p = 0.0001) and smoking (p = 0.03). CONCLUSION: The aforementioned factors pose a risk for cardiotoxicity. We found postmenopausal status, hypertension, obesity, previous coronary artery disease and smoking to be associated with an increased risk of cardiac dysfunction in women using trastuzumab. While administering trastuzumab to women who have these conditions, one must be aware of the risk of cardiotoxicity of trastuzumab.
BACKGROUND:Trastuzumab is a recombinant humanized monoclonal antibody used to treat humanepidermal growth factor receptor 2 positive breast cancer, with recognized associated cardiotoxicity. In this retrospective observational study, we investigated associated cardiotoxicity on clinical outcomes using trastuzumab in women referred to our clinic. MATERIALS AND METHODS: The study was made up of 111 women with humanepidermal growth factor receptor 2-overexpressing breast cancer who received trastuzumab in the Medical Oncology Department, between 2010 and 2013. RESULTS: A > 10% reduction of the baseline fraction of the left ventricular ejection fraction was observed in 18 (16.21%) women. Two individuals (1.8%) suffered from symptomatic heart failure, seven women showed cardiac symptoms and nine women showed asymptomatic decline of left ventricular ejection fraction. Risk factors for cardiotoxicity in the group included: postmenopausal status (p = 0.01), hypertension (p = 0.002), obesity (p = 0.0001), previously diagnosed coronary artery disease (p = 0.0001) and smoking (p = 0.03). CONCLUSION: The aforementioned factors pose a risk for cardiotoxicity. We found postmenopausal status, hypertension, obesity, previous coronary artery disease and smoking to be associated with an increased risk of cardiac dysfunction in women using trastuzumab. While administering trastuzumab to women who have these conditions, one must be aware of the risk of cardiotoxicity of trastuzumab.
Authors: Marilyn L Kwan; Richard K Cheng; Carlos Iribarren; Romain Neugebauer; Jamal S Rana; Mai Nguyen-Huynh; Zaixing Shi; Cecile A Laurent; Valerie S Lee; Janise M Roh; Hanjie Shen; Eileen Rillamas-Sun; Margarita Santiago-Torres; Dawn L Hershman; Lawrence H Kushi; Heather Greenlee Journal: J Clin Oncol Date: 2022-01-13 Impact factor: 50.717
Authors: Somaira Nowsheen; Paul V Viscuse; Ciara C O'Sullivan; Nicole P Sandhu; Tufia C Haddad; Anne Blaes; Jennifer Klemp; Lara Nhola; Joerg Herrmann; Kathryn J Ruddy Journal: Curr Breast Cancer Rep Date: 2017-07-14
Authors: Jennifer Y Sheng; Dipali Sharma; Gerald Jerome; Cesar Augusto Santa-Maria Journal: Oncology (Williston Park) Date: 2018-08-15 Impact factor: 2.533